TGF-β Receptor 1 (TGFBR1) is a transmembrane serine/threonine kinase that serves as the primary type I receptor for transforming growth factor-beta ligands in the nervous system. This protein plays critical roles in mediating TGF-β signaling that regulates neuroinflammation, neuronal survival, synaptic plasticity, and glial function.
TGF-β Receptor 1 (TGFBR1) is a transmembrane serine/threonine kinase that serves as the primary type I receptor for transforming growth factor-beta ligands in the nervous system. This protein plays critical roles in mediating TGF-β signaling that regulates neuroinflammation, neuronal survival, synaptic plasticity, and glial function.
Overview
TGFBR1 (Transforming Growth Factor Beta Receptor 1) is a 53 kDa transmembrane receptor kinase that transduces extracellular TGF-β signals into cellular responses[@massague2000]. As the primary type I receptor, TGFBR1 phosphorylates downstream SMAD proteins (SMAD2/3) to regulate gene expression programs controlling neuronal survival, neuroinflammation, and synaptic plasticity[@todo2020].
Protein Information
Protein Structure
Extracellular Domain (1-190 aa)
The extracellular domain contains:
cysteine-rich domain (CR): Mediates ligand binding and receptor oligomerization
The study of Tgf Β Receptor 1 (Tgfbr1) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
Massague J, et al, TGF-beta signal transduction (2000)
Todo R, et al, TGF-beta in the nervous system (2020)
Kane CJ, et al, TGF-beta neuroprotection in PD models (2018)
Brionne TC, et al, Loss of TGF-beta signaling in neurons (2021)
Tichauer JE, et al, TGF-beta and BBB (2020)
Ferguson L, et al, TGF-beta and synaptic plasticity (2019)
Caraci F, et al, TGF-beta alterations in AD (2021)
Wyss-Coray T, et al, TGF-beta and neuroinflammation (2020)
Mousseau M, et al, TGFBR1 expression and cognitive decline (2021)
Wyss-Coray T, et al, TGF-beta and amyloid clearance (2020)
Rai SN, et al, TGF-beta protection in dopaminergic neurons (2022)
Reynolds CH, et al, TGF-beta and alpha-synuclein (2021)
Tong J, et al, TGFBR1 in PD (2019)
Dormann D, et al, TGF-beta in ALS (2020)
Ilieva H, et al, TGF-beta pathway in ALS (2019)
Gellibert F, et al, SB-525334, a selective TGFBR1 inhibitor (2006)
Fu H, et al, SD-208, a TGF-beta RI inhibitor (2020)
Zhang B, et al, LY2109761 in cancer therapy (2019)
Sakauchi M, et al, TGF-beta agonists for neuroprotection (2021)
Akhurst RJ, et al, TGFBR1 agonists in disease (2021)